James Phillips, a physician and biopharma executive, is to become chief executive of Paion AG on 16 October succeeding the company’s co-founder and CEO Wolfgang Söhngen who is retiring. The management transition comes as the company’s lead product remimazolam is under review at the US Food and Drug Administration for approval as a treatment for procedural sedation. Dr Phillips will lead the prospective commercialisation of the product. He was most recently managing director of the German vaccine company Imevax GmbH and prior to that, CEO of the UK oncology company Midatech Pharma Plc. Earlier in his career he was a senior executive at Johnson & Johnson Inc and Novartis. He holds a master of business administration from the City University Business School in London, UK.
Paion announced the appointment on 22 August 2019.
Copyright 2019 Evernow Publishing Ltd.